Lancet

(ISSN: 0140-6736, 1474-547X)

Table of Contents

From Lancet

2021 - 396 (10267)

  • A complex karyotype and a genetic mutation in acute myeloid leukaemia. 
  • PD-1 inhibitors for urothelial cancer: combination or sequential therapy? 
  • PD-1 inhibitors for urothelial cancer: combination or sequential therapy? - Authors' reply. 
  • Triple artemisinin-based combination therapies for malaria: proceed with caution - Authors' reply. 
  • Triple artemisinin-based combination therapies for malaria: proceed with caution. 
  • Renal replacement therapy in acute kidney injury - Authors' reply. 
  • Renal replacement therapy in acute kidney injury. 
  • Renal replacement therapy in acute kidney injury. 
  • Management of primary spontaneous pneumothorax: less is more. 
  • Management of primary spontaneous pneumothorax: less is more - Authors' reply. 
  • Highlights 2020: framing health stories. 
  • Caribbean rainy season batters health care. 
  • Havana syndrome might be the result of energy pulses. 
  • 2020 Wakley Prize: space for compassion. 
  • Is it time for injectable antiretroviral therapy for HIV? 
  • Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. 
  • Global health-care systems must prioritise rehabilitation. 
  • Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. 
  • The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. 
  • Data-driven policies needed to turn the tide on diabetes. 
  • Rury Holman: the science of diabetes and a life of trials. 
  • Offline: The lessons of smallpox eradication for COVID-19. 
  • Science during COVID-19: where do we go from here? 
  • Is NHS Test and Trace exacerbating COVID-19 inequalities? 
  • Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. 
  • Age and frailty in COVID-19 vaccine development. 
 
 

Journal Information